Risk Stratification and Initial Management of Common ID Emergencies: Improving Outcomes in the Golden Hours

Faculty

This activity has 4 faculty members associated with it.
Click Here to View All

Peter M. DeBlieux, MD, FACEP
Director of Emergency Medicine Services
Medical Center of Louisiana at New Orleans
Clinical Professor & Director of Resident and Faculty Development
LSUHSC Emergency Medicine
Clinical Professor of Surgery
Tulane School of Medicine

Kenneth V. Leeper Jr., MD, FCCP
Associate Professor of Medicine
Department of Medicine
Division of Pulmonary, Allergy and Critical Care Medicine
Emory University School of Medicine

Ellen M. Slaven, MD, FACEP, FAAEM
Clinical Assistant Professor of Medicine
Louisiana State University Health Services Center
Department of Medicine
Section of Emergency Medicine
Charity Hospital

David A. Talan, MD, FACEP, FIDSA
Chair, Department of Emergency Medicine
Olive View-UCLA Medical Center
Professor of Medicine and Emergency Medicine
David Geffen School of Medicine at UCLA

Needs Statement

Emergency Department (ED) physicians commonly serve as the first healthcare provider contact for patients with a variety of community-acquired cutaneous and respiratory tract infections. As such, they must rapidly make a diagnosis, determine the severity of the process, and institute appropriate empiric therapy. In recent years, drug-resistant bacterial infections have become more common in the community, particularly CA-MRSA. In addition, the spectrum of pneumonias has been expanded to include healthcare-associated pneumonia (HCAP).

Utilizing a multidisciplinary panel of experts from Emergency Medicine, Critical Care and Infectious Disease, a number of issues will be examined and discussed to establish a consensus of diagnostic and therapeutic strategies related to drug-resistant infections seen in the ED. This review will provide clinical experience and evidence for identifying, treating and effectively managing patients with multidrug-resistant infections.

Target Audience

This CME activity is desinged for ED physicians, surgeons, hospitalists, primary care physicians, and other healthcare professionals involved in the evaluation and treatment of patients with serious infections.

Objectives

At the end of this educational activity, particpants should be able to: 

1. Outline the key issues in identifying and managing patients with infectious disorders and how the changing epidemiology and resistance patterns complicate the selection of appropriate treatment;
2. List key principles of current and novel antibiotic therapy and review when to use alternate agents;
3. Describe optimal use of antibiogram data and microbiology laboratory—when to culture, how to culture—to clarify the diagnosis;
4. Relate the importance of initial, empiric broad-spectrum antibiotic therapy with the need for subsequent de-escalation.

Accreditation

Medicine
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Kentucky College of Medicine and p-value communications. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Each physician should claim only those hours of credit actually spent in the educational activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

Faculty Disclosure

Dr. DeBlieux serves on the speaker's bureau for Merck & Co., Inc., Pfizer, Inc. and Ortho-McNeil, Inc; and serves as a consultant to Merck & Co., Inc. and Ortho-McNeil, Inc.

Dr. Leeper serves on the speaker's bureau for Ortho-McNeil, Inc. and Pfizer, Inc.; serves as a consultant to Ortho-McNeil, Inc. and Pfizer, Inc.; and has received research support from Kimberly-Clark Health Care.

Dr. Slaven reports no relevant financial relationships with commercial interests of healthcare products or services related to this activity.

Dr. Talan serves on the speaker's bureau Pfizer, Inc.; serves as a consultant to Astellas Pharma Inc., Ortho-McNeil, Inc., Pfizer, Inc., Replidyne, Inc. and Schering-Plough Corporation; and has received research support from Ortho-McNeil, Inc. and Pfizer, Inc.

Activity Sponsorship

This activity is jointly sponsored by the University of Kentucky and p-value communications. Supported by an educational grant from Ortho-McNeil, Division of Ortho McNeil-Janssen Pharmaceutical, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC.